Trial Profile
A phase III, double-blind, comparative study of NE-58095 (once-monthly formulation)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis; Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Ajinomoto Pharma; Takeda
- 27 May 2016 New trial record